CHARGEPOINT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ChargePoint Holdings, Inc. – CHPT
NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind... Read more.
Marquest Mutual Funds Inc. – Explorer Series Fund Declares Eligible Dividend and Share Consolidation
TORONTO–(BUSINESS WIRE)–Marquest Mutual Funds Inc. (the “Corporation”) announces dividends for the Marquest Mutual Funds Inc. – Explorer Series... Read more.
Porzio, Bromberg & Newman Named Winner of Financial Times Innovative Lawyers in Healthcare & Life Sciences Award
Porzio takes honor over Am Law 100 giants, becomes one of the first midsized firms ever recognized in Innovative Lawyers award series. MORRISTOWN, N.J.–(BUSINESS... Read more.
KBRA Assigns Preliminary Ratings to BX 2023-XL3
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA announces the assignment of preliminary ratings to five classes of BX 2023-XL3, a CMBS single-borrower securitization.... Read more.
Federman & Sherwood Investigates Big Brothers Big Sisters of America for Data Breach
OKLAHOMA CITY–(BUSINESS WIRE)–$BBBSA #BBBSA–The law firm of Federman & Sherwood has initiated an investigation into Big Brothers Big Sisters... Read more.
Federman & Sherwood Investigates Bluefield University for Data Breach
OKLAHOMA CITY–(BUSINESS WIRE)–#Bluefield–The law firm of Federman & Sherwood has initiated an investigation into Bluefield University, with... Read more.
Avolon Announces Pricing of US$400 Million Senior Unsecured Notes Offering
DUBLIN–(BUSINESS WIRE)–Avolon Holdings Limited (“Avolon”), a leading global aviation finance company, announces the pricing of a private offering... Read more.
Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide... Read more.
Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide... Read more.
Touch Detective 3 + The Complete Case Files Release Date Set
Collection Coming to Nintendo Switch™ on March 28, 2024 SANTA ANA, Calif.–(BUSINESS WIRE)–Nicalis officially announces that Touch Detective 3 + The... Read more.